1292 related articles for article (PubMed ID: 24062400)
21. [Prognostic significance of minimal residual disease detected by multiparameter flow cytometry in acute myeloid leukemia].
Wang YZ; Liu YR; Zhu HH; Wu HH; Cao H; Chan Y; Hao L; Jiang B; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):551-6. PubMed ID: 19549362
[TBL] [Abstract][Full Text] [Related]
22. Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.
Köhnke T; Sauter D; Ringel K; Hoster E; Laubender RP; Hubmann M; Bohlander SK; Kakadia PM; Schneider S; Dufour A; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Spiekermann K; Subklewe M
Leukemia; 2015 Feb; 29(2):377-86. PubMed ID: 24912430
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.
Corbacioglu A; Scholl C; Schlenk RF; Eiwen K; Du J; Bullinger L; Fröhling S; Reimer P; Rummel M; Derigs HG; Nachbaur D; Krauter J; Ganser A; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(23):3724-9. PubMed ID: 20625124
[TBL] [Abstract][Full Text] [Related]
24. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
Wang L; Gao L; Xu S; Gong S; Liu M; Qiu H; Xu X; Ni X; Chen L; Lu S; Chen J; Song X; Zhang W; Yang J; Hu X; Wang J
Ann Hematol; 2014 Oct; 93(10):1685-94. PubMed ID: 24844781
[TBL] [Abstract][Full Text] [Related]
25. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia.
Buccisano F; Maurillo L; Gattei V; Del Poeta G; Del Principe MI; Cox MC; Panetta P; Consalvo MI; Mazzone C; Neri B; Ottaviani L; Fraboni D; Tamburini A; Lo-Coco F; Amadori S; Venditti A
Leukemia; 2006 Oct; 20(10):1783-9. PubMed ID: 16838027
[TBL] [Abstract][Full Text] [Related]
26. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation.
Venditti A; Maurillo L; Buccisano F; Del Poeta G; Mazzone C; Tamburini A; Del Principe MI; Consalvo MI; De Fabritiis P; Cudillo L; Picardi A; Franchi A; Lo-Coco F; Amadori S
Leukemia; 2003 Nov; 17(11):2178-82. PubMed ID: 14576731
[TBL] [Abstract][Full Text] [Related]
27. Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.
Deng DX; Zhu HH; Liu YR; Chang YJ; Ruan GR; Jia JS; Jiang H; Jiang Q; Zhao XS; Huang XJ
Leuk Lymphoma; 2019 Sep; 60(9):2181-2189. PubMed ID: 30773106
[TBL] [Abstract][Full Text] [Related]
28. The role of multiparameter flow cytometry for disease monitoring in AML.
Kern W; Bacher U; Haferlach C; Schnittger S; Haferlach T
Best Pract Res Clin Haematol; 2010 Sep; 23(3):379-90. PubMed ID: 21112037
[TBL] [Abstract][Full Text] [Related]
29. Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Piciocchi A; Del Principe MI; Sarlo C; Di Veroli A; Panetta P; Irno-Consalvo M; Nasso D; Ditto C; Refrigeri M; De Angelis G; Cerretti R; Arcese W; Sconocchia G; Lo-Coco F; Amadori S; Venditti A
Am J Hematol; 2015 Feb; 90(2):125-31. PubMed ID: 25377359
[TBL] [Abstract][Full Text] [Related]
30. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
31. Minimal residual disease in acute myeloid leukemia: coming of age.
Paietta E
Hematology Am Soc Hematol Educ Program; 2012; 2012():35-42. PubMed ID: 23233558
[TBL] [Abstract][Full Text] [Related]
32. A method comparison study of flow cytometry and cytomorphology to determine the percentages of blasts in patients with acute leukemia after induction and consolidation chemotherapy.
Wongprajun S; Auewarakul CU
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S157-64. PubMed ID: 20364570
[TBL] [Abstract][Full Text] [Related]
33. [Flow cytometric monitoring of minimal residual diseases in patients with acute leukemia after allogeneic hemapoietic stem cell transplantation].
Gao YQ; Wu T; Wang H; Tong CR; Zhang WJ; Wang JB; Lu Y; Zhao YL; Zhou JR; Sun Y; Zhang YC; Ji SQ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):84-7. PubMed ID: 22730653
[TBL] [Abstract][Full Text] [Related]
34. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.
Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N
Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957
[TBL] [Abstract][Full Text] [Related]
35. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.
Zeijlemaker W; Kelder A; Oussoren-Brockhoff YJ; Scholten WJ; Snel AN; Veldhuizen D; Cloos J; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2016 Mar; 30(3):708-15. PubMed ID: 26373238
[TBL] [Abstract][Full Text] [Related]
36. Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilm's tumor 1 levels.
Rossi G; Minervini MM; Melillo L; di Nardo F; de Waure C; Scalzulli PR; Perla G; Valente D; Sinisi N; Cascavilla N
Ann Hematol; 2014 Jul; 93(7):1149-57. PubMed ID: 24554303
[TBL] [Abstract][Full Text] [Related]
37. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
38. History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
Rashidi A; Linden MA; DeFor TE; Warlick E; Bejanyan N; Yohe S; Weisdorf DJ; Ustun C
Am J Hematol; 2017 Oct; 92(10):1032-1036. PubMed ID: 28646534
[TBL] [Abstract][Full Text] [Related]
39. [Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study].
Reinhardt D; Langebrake C; Creutzig U; Vormoor J; Brune C; Thorwesten M; Ingiliz P; Hrusak O; Dworzak M; Griesinger F
Klin Padiatr; 2002; 214(4):179-87. PubMed ID: 12165899
[TBL] [Abstract][Full Text] [Related]
40. [A new prognostic stratification for patients with acute myeloid leukemia].
Jiang B; Mi YC; Lin D; Cai XJ; Fu MW; Li W; Wang Y; Liu XP; Xue YP; Bian SG; Wang JX
Zhonghua Nei Ke Za Zhi; 2009 Apr; 48(4):316-20. PubMed ID: 19576124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
